Mission Bay Capital
VC Fund
San Francisco, United States
Mission Bay Capital is a venture capital firm for early-stage investments.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 10%
- Fund size:
- $60M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Mission Bay Capital invests in
Stages Mission Bay Capital invests in
Countries Mission Bay Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ralph E. Christofferson
|
|||
Brian Atwood
|
|||
David DesJardins
|
|||
Doug Cameron
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 22 (55%)
- Health Care 16 (40%)
- Therapeutics 14 (35%)
- Medical 6 (15%)
- Medical Device 3 (8%)
Stage
- Series B 13 (33%)
- Series A 11 (28%)
- Seed 6 (15%)
- Funding Round 3 (8%)
- Angel 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ralph E. Christofferson
Partner
|
Partner | Total investments: 0 | Find email | |
|
Brian Atwood
Managing Partner
|
Managing Partner | Total investments: 12 | Find email | |
Brook Byers
Partner
|
Partner | Total investments: 51 | Find email | |
|
David DesJardins
Investor
|
Investor | Total investments: 2 | Find email | |
|
Doug Cameron
Partner
|
Partner | Total investments: 1 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
QurAlis
|
QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M / Series B / Mar 09, 2023 | |
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $7M / Series A / Nov 02, 2021 | |
Nobell Foods
|
Alpine Roads unlocks the power of plants to create the next generation of animal-based food substitutes. | $75M / Series B / Jul 22, 2021 | |
Symbiome
|
Symbiome offers skincare as nature intended solution which is scientifically and intentionally formulated using ancestral ingredients. It was founded in 2017 and is headquartered in San Francisco, California. | $15M / Venture - Series Unknown / Sep 14, 2020 | |
|
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $38M / Series A / Apr 22, 2020 | |
Glycomine
|
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $33M / Series B / Aug 07, 2019 | |
Alector
|
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with uniquefunctional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams. | $133M / Series E / Jul 25, 2018 | |
GraphWear Technologies
|
GraphWear is reinventing the way we map human health. Pioneering a no-needle, no-blood approach to disease monitoring, GraphWear’s technology offers the first genuinely non-invasive method to map patient health, unlocking a new adherence for some of the most significant chronic diseases. By empowering access to accurate and timely healthinformation in an easy-to-use format, GraphWear aims to drive greater efficiency across diagnosis, management, and care. GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer. | $4.2M / Series A / Apr 17, 2018 | |
Wildtype
|
Wild Type is an agtech platform based in San Francisco, California.Wild Type aims to create clean and sustainable fish and meat. They use cellular agriculture technologies to address the most pressing challenges of the generation: climate change, food security, and health. They are looking for committed scientists to fundamentally redefine howthe world sources healthy and delicious meat. | $3.5M / Seed / Mar 30, 2018 | |
ViewPoint Therapeutics
|
ViewPoint Therapeutics is a biotechnology company dedicated to the development of treatments for diseases of protein misfolding, including cataracts. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, providingphysicians with drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases. | $35M / Series B / Mar 05, 2018 | |
| See all 40 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Mission Bay Capital invest in?
Mission Bay Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mission Bay Capital?
Public channels for Mission Bay Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mission Bay Capital?
The team at Mission Bay Capital includes Ralph E. Christofferson (Partner), Brian Atwood (Managing Partner) and Brook Byers (Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
